Orbimed Advisors LLC Theravance Biopharma, Inc. Transaction History

Orbimed Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.41 - $10.34 $15.8 Million - $19.5 Million	-1,884,463 Reduced 57.9%	1,370,250 $12.4 Million
Q1 2022 May 16, 2022	SELL	$8.33 - $12.96 $22.7 Million - $35.2 Million	-2,719,822 Reduced 45.52%	3,254,713 $31.1 Million
Q4 2021 Feb 14, 2022	BUY	$7.42 - $11.05 $588,969 - $877,104	79,376 Added 1.35%	5,974,535 $66 Million
Q3 2021 Nov 15, 2021	BUY	$6.77 - $14.41 $9.01 Million - $19.2 Million	1,331,114 Added 29.17%	5,895,159 $43.6 Million
Q2 2021 Aug 16, 2021	SELL	$14.52 - $22.46 $24 Million - $37.2 Million	-1,655,065 Reduced 26.61%	4,564,045 $66.3 Million
Q3 2020 Nov 16, 2020	BUY	$14.79 - $22.49 $54.2 Million - $82.4 Million	3,664,640 Added 143.46%	6,219,110 $92 Million
Q2 2020 Aug 14, 2020	BUY	$20.64 - $30.69 $48.4 Million - $71.9 Million	2,342,925 Added 1107.53%	2,554,470 $53.6 Million
Q1 2020 May 15, 2020	BUY	$17.84 - $31.21 $3.77 Million - $6.6 Million	211,545 New	211,545 $4.89 Million

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.